Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 13/2011

01-09-2011 | Adis Drug Profile

Pirfenidone

In Idiopathic Pulmonary Fibrosis

Author: Natalie J. Carter

Published in: Drugs | Issue 13/2011

Login to get access

Abstract

Pirfenidone is an orally administered pyridine that has orphan designation for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF) in the EU.
Pirfenidone 2403 mg/day for 72 weeks administered to patients with IPF was associated with a significantly lower mean decline in the percent predicted forced vital capacity than placebo (primary endpoint) according to data from one of two randomized, double-blind, multinational trials (studies 004 and 006 [also known as the CAPACITY trials]), and data from a pooled analysis of both trials.
In another randomized, double-blind, multicentre Japanese trial, the adjusted mean in the change in vital capacity from baseline to week 52 was significantly lower in patients with IPF who received pirfenidone 1800 mg/day (considered to be comparable to the 2403 mg/day dose in studies 004 and 006 on a weight-normalized basis) than in those who received placebo (primary endpoint).
Pirfenidone had an acceptable tolerability profile in clinical trials, with most adverse events being mild to moderate in severity.
Literature
1.
Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011 Mar 15; 183(6): 788–824PubMedCrossRef
2.
Hauber H-P, Blaukovitsch M. Current and future treatment options in idiopathic pulmonary fibrosis. Inflamm Allergy Drug Targets 2010 Jul 1; 9(3): 158–72PubMedCrossRef
3.
4.
Bouros D. Pirfenidone for idiopathic pulmonary fibrosis [letter]. Lancet 2011 May 21; 377(9779): 1727–9PubMedCrossRef
5.
6.
Macías-Barragán J, Sandoval-Rodríguez A, Navarro-Partida J, et al. The multifaceted role of pirfenidone and its novel targets. Fibrogenesis Tissue Repair 2010; 3: 16PubMed
7.
Jackson RM, Gomez-Marin O. Development and utility of pirfenidone in the treatment of idiopathic pulmonary fibrosis: review of preclinical science and recent clinical trials. Transpl Res Risk Manag 2011; 3: 55–63CrossRef
8.
Oku H, Shimizu T, Kawabata T, et al. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol 2008 Aug 20; 590 (1-3): 400–8CrossRef
9.
Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on transforming growth factor-b gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 1999 Oct; 291(1): 367–73PubMed
10.
11.
Gurujeyalakshmi G, Hollinger MA, Giri SN, et al. Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level. Am J Physiol Lung Cell Mol Physiol 1999 Feb 1; 276(2): L311–8
12.
Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 1999 Apr; 289(1): 211–8PubMed
13.
Iyer SN, Wild JS, Schiedt MJ, et al. Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. J Labs Clin Med 1995; 125: 779–85
14.
Schaefer CJ, Ruhrmund DW, Pan L, et al. Antifibrotic activities of pirfenidone in animal models. Eur Respir Rev 2011 Jun 1; 20(120): 85–97PubMedCrossRef
15.
Kakugawa T, Mukae H, Hayashi T, et al. Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosis. Eur Respir J 2004 Jul; 24(1): 57–65PubMedCrossRef
16.
Iyer SN, Hyde DM, Giri SN. Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation. Inflammation 2000 Oct; 24(5): 477–91PubMedCrossRef
17.
Spond J, Case N, Chapman RW, et al. Inhibition of experimental acute pulmonary inflammation by pirfenidone. Pulm Pharmacol Ther 2003 Aug; 16(4): 207–14PubMedCrossRef
18.
Oku H, Nakazato H, Horikawa T, et al. Pirfenidone suppresses tumor necrosis factor-α, enhances interleukin-10 and protects mice from endotoxic shock. Eur J Pharmacol 2002 Jun 20; 446(1-3): 167–76PubMedCrossRef
19.
Nakazato H, Oku H, Yamane S, et al. A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-α at the translational level. Eur J Pharmacol 2002 Jun 20; 446(1–3): 177–85PubMedCrossRef
20.
Koyama S, Kamijyo S, Hashizume M, et al. Pirfenidone attenuates the release of neutrophil (NCA) and monocyte chemotactic activity (MCA) from human lung fibroblasts (FLH-1) in response to tumor necrosis factor (TNF)-alpha [abstract]. Am J Respir Crit Care Med 2010 May 1; 181 Suppl.: A3529
21.
Misra H, Rabideau C. Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals. Molec Cell Biochem 2000 Jan; 204(1–2): 119–26PubMedCrossRef
22.
Giri SN, Leonard S, Shi X, et al. Effects of pirfenidone on the generation of reactive oxygen species in vitro. J Environ Pathol Toxicol Oncol 1999; 18(3): 169–77PubMed
23.
Mitani Y, Sato K, Muramoto Y, et al. Superoxide scavenging activity of pirfenidone-iron complex. Biochem Biophys Res Commun 2008 Jul; 372(1): 19–23PubMedCrossRef
24.
Kaneko M, Inoue H, Nakazawa R, et al. Pirfenidone induces intercellular adhesion molecule-1 (ICAM-1) down-regulation on cultured human synovial fibroblasts. Clin Exp Immunol 1998; 113: 72–6PubMedCrossRef
25.
Shi S, Wu J, Chen H, et al. Single-and multiple-dose pharmacokinetics of pirfenidone, an antifibrotic agent, in healthy Chinese volunteers. J Clin Pharmacol 2007 Oct; 47(10): 1268–76PubMedCrossRef
26.
Rubino CM, Bhavnani SM, Ambrose PG, et al. Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults. Pulm Pharmacol Ther 2009 Aug; 22(4): 279–85PubMedCrossRef
27.
28.
Raghu G, Johnson WC, Lockhart D, et al. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label phase II study. Am J Respir Crit Care Med 1999 Apr 1; 159(4): 1061–9PubMed
29.
Nagai S, Hamada K, Shigematsu M, et al. Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern Med 2002 Dec; 41(12): 1118–23PubMedCrossRef
30.
Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005 May 1; 171(9): 1040–7PubMedCrossRef
31.
Noble PW, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377(9779): 1760–9PubMedCrossRef
32.
Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010 Apr; 35(4): 821–9PubMedCrossRef
33.
Costabel U, Albera C, Bradford W, et al. Pirfenidone dose-response in patients with idiopathic pulmonary fibrosis (IPF): a comprehensive analysis of outcomes in CAPACITY 2 [abstract no. 388]. 20th Annual Congress of the European Respiratory Society; 2010 Sep 18–22; Barcelona
34.
Valeyre D, Albera C, Bradford W, et al. The effect of treatment with pirfenidone on death or lung transplantation in patients with idiopathic pulmonary fibrosis (IPF): analysis of outcomes in the CAPACITY (CAP) trials [abstract no. 391]. 20th Annual Congress of the European Respiratory Society; 2010 Sep 18–22; Barcelona
35.
Ley B, Collard HR, King TE. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011 Feb; 183(4): 431–40PubMedCrossRef
36.
Albera C, Bradford W, Costabel U, et al. The magnitude of pirfenidone treatment effect in patients with idiopathic pulmonary fibrosis (IPF): a pooled analysis of outcomes in the CAPACITY (CAP) studies [abstract no. 389]. 20th Annual Congress of the European Respiratory Society; 2010 Sep 18–22; Barcelona
37.
38.
Metadata
Title
Pirfenidone
In Idiopathic Pulmonary Fibrosis
Author
Natalie J. Carter
Publication date
01-09-2011
Publisher
Springer International Publishing
Published in
Drugs / Issue 13/2011
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/11207710-000000000-00000

Other articles of this Issue 13/2011

Drugs 13/2011 Go to the issue

Review Article

Glucagon-like Peptide-1 Analogues for Type 2 Diabetes Mellitus

Review Article

Triple Antiplatelet Therapy in Acute Coronary Syndromes

Leading Article

Tissue-Selective Estrogen Complex Bazedoxifene and Conjugated Estrogens for the Treatment of Menopausal Vasomotor Symptoms

Leading Article

Vaccination Strategies in Lymphomas and Leukaemias

Adis Drug Evaluation

Ustekinumab

Review Article

Pharmacological Modulation of Arterial Stiffness